This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (58)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Evidence-Based Medicine  • Neurology  • Review  • Stroke  • Lipids and Lipid Disorders  • Cardiovascular System, Other  • Alert me on articles by topic

A Meta-analysis of Randomized Trials

Jean-Christophe Corvol, MD; Anissa Bouzamondo, MD; Marc Sirol, MD; Jean-Sébastien Hulot, MD; Paola Sanchez, MD; Philippe Lechat, MD, PhD

Arch Intern Med. 2003;163:669-676.

Background  Previous overviews suggested that hydroxymethyl glutaryl coenzyme A reductase inhibitors (statins), but not other lipid-lowering therapy (LLT), may reduce stroke incidence in coronary patients.

Objective  To investigate the amplitude and sources of heterogeneity of LLT effects on stroke prevention.

Methods  We searched the literature from 1966 to 2001 and then conducted a meta-analysis including randomized trials of primary and secondary coronary heart disease prevention, testing statins, nonstatin drugs, diet, or other interventions and providing data on stroke incidence.

Results  The meta-analysis (38 trials, 83 161 patients, mean follow-up of 4.7 years) showed a significant relative risk reduction (RRR) of strokes by LLT of 17% (P<.001), without significant heterogeneity between trials and between subgroups according to either the type of prevention (primary or secondary) or the type of LLT. The most substantial effects were obtained, however, with statins (RRR, 26%). Effect model analysis showed that treatment benefit appeared constant whatever the risk of stroke, suggesting that LLT may be effective in a population with a higher risk of stroke. Weighted regression showed a significant correlation between RRR of stroke and total cholesterol levels (baseline, final, and change). Only final cholesterol allowed clear separation between benefit (RRR>0) and no effect (RRR<0) of LLT on stroke incidence, with a cutoff for benefit of 232 mg/dL (6.0 mmol/L).

Conclusion  Lipid-lowering therapy reduces stroke incidence in coronary patients, especially when total cholesterol level is lowered to less than 232 mg/dL (6.0 mmol/L), which explains the best results being obtained with statins.

From the Service de Pharmacologie, Centre Hospitalo-Universitaire Pitié-Salpêtrière, Paris, France.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Review: lower total cholesterol is associated with reduced risk of death from ischaemic heart disease but not stroke
Hackam
Evid. Based Med. 2008;13:87-87.
FULL TEXT  

The 3-Hydroxy-3-Methylglutaryl-CoA Reductase Inhibitor Lovastatin Reduces Severity of L-DOPA-Induced Abnormal Involuntary Movements in Experimental Parkinson's Disease
Schuster et al.
J. Neurosci. 2008;28:4311-4316.
ABSTRACT | FULL TEXT  

Influence of Atorvastatin Treatment on L-Arginine Cerebrovascular Reactivity and Flow-Mediated Dilatation in Patients With Lacunar Infarctions
Pretnar-Oblak et al.
Stroke 2006;37:2540-2545.
ABSTRACT | FULL TEXT  

Serum cholesterol, haemorrhagic stroke, ischaemic stroke, and myocardial infarction: Korean national health system prospective cohort study
Ebrahim et al.
BMJ 2006;333:22.
ABSTRACT | FULL TEXT  

Medication-Attributed Adverse Effects in Placebo Groups: Implications for Assessment of Adverse Effects
Rief et al.
Arch Intern Med 2006;166:155-160.
ABSTRACT | FULL TEXT  

Lipid Testing and Lipid-Lowering Therapy in Hospitalized Ischemic Stroke and Transient Ischemic Attack Patients: Results From a Statewide Stroke Registry
Mullard et al.
Stroke 2006;37:44-49.
ABSTRACT | FULL TEXT  

Managing Abnormal Blood Lipids: A Collaborative Approach
Fletcher et al.
Circulation 2005;112:3184-3209.
ABSTRACT | FULL TEXT  

Update in Endocrinology
Wartofsky
ANN INTERN MED 2005;143:673-682.
FULL TEXT  

Review: statins reduce non-fatal and fatal strokes in patients with and without coronary heart disease
Kingsbury
Evid. Based Nurs. 2005;8:86-86.
FULL TEXT  

Statin Use and Survival Outcomes in Elderly Patients With Heart Failure
Ray et al.
Arch Intern Med 2005;165:62-67.
ABSTRACT | FULL TEXT  

Expanding Indications for Statins in Cerebral Ischemia: A Quantitative Study
Ovbiagele et al.
Arch Neurol 2005;62:67-72.
ABSTRACT | FULL TEXT  

Novel Approach to Examining First Cardiovascular Events After Hypertension Onset
Lloyd-Jones et al.
Hypertension 2005;45:39-45.
ABSTRACT | FULL TEXT  

Cholesterol lowering with simvastatin reduced stroke in patients with, or at risk of, vascular disease
Claiborne Johnston
Evid. Based Med. 2004;9:143-143.
FULL TEXT  

Cholesterol as a Risk Factor for Stroke: The Fugitive?
Piechowski-Jozwiak and Bogousslavsky
Stroke 2004;35:1523-1524.
FULL TEXT  

Cholesterol Is Associated With Stroke, but Is Not a Risk Factor
Thrift
Stroke 2004;35:1524-1525.
FULL TEXT  

Beyond the Laboratory: Clinical Implications for Statin Pleiotropy
Halcox and Deanfield
Circulation 2004;109:II-42-II-48.
ABSTRACT | FULL TEXT  

Statins After Ischemic Stroke and Transient Ischemic Attack: An Advisory Statement From the Stroke Council, American Heart Association, and American Stroke Association
The Stroke Council
Arterioscler. Thromb. Vasc. Bio. 2004;24:793-793.
FULL TEXT  

Statins After Ischemic Stroke and Transient Ischemic Attack: An Advisory Statement From the Stroke Council, American Heart Association and American Stroke Association
The Stroke Council
Stroke 2004;35:1023-1023.
FULL TEXT  

Current and future concepts in stroke prevention
O'Rourke et al.
CMAJ 2004;170:1123-1133.
ABSTRACT | FULL TEXT  

Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease
Emberson et al.
Eur Heart J 2004;25:484-491.
ABSTRACT | FULL TEXT  

JournalScan
Malik
Heart 2003;89:695-695.
FULL TEXT  

Review: Lipids and stroke
Buckley
British Journal of Diabetes & Vascular Disease 2003;3:170-176.
ABSTRACT